Academic Journal
Q2Frontiers in Chemical Biology
About Frontiers in Chemical Biology
Frontiers in Chemical Biology is a scholarly journal published by Frontiers Media SA. SCImago 2025 lists it in Q2, with an SJR of 0.435 and H-index of 6.
Coverage: 2022-2026. Research categories: Chemistry (miscellaneous) (Q2); Pharmacology, Toxicology and Pharmaceutics (miscellaneous) (Q2); Structural Biology (Q4).
Open-access policies and author information
Reported in the official DOAJ public CSV snapshot (2026-09-01), downloaded 2026-10-03. Record updated 2026-03-12. This snapshot does not establish today’s listing status or fee quotation.
Publisher policy links recorded by DOAJ
- Aims and scope ↗
- Editorial board ↗
- Instructions for authors ↗
- Peer-review policy ↗
- Publication fees ↗
- Fee waivers ↗
- Licence terms ↗
- Copyright policy ↗
- Preservation policy ↗
Source: DOAJ journal record. Journal metadata is distributed by DOAJ under CC0. Confirm current fees, tax, eligibility and waiver terms with the publisher.
Source-backed journal facts
Topics in published research
Metal complexes synthesis and properties; Vanadium and Halogenation Chemistry; Polyoxometalates: Synthesis and Applications; Enzyme Structure and Function; Biochemical and Molecular Research; Protein Structure and Dynamics.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
A bifunctional carborane-quinazoline combines tumor growth inhibition and boron delivery for boron neutron capture therapy in melanoma and non-small cell lung cancer models
María Alejandra Dagrosa, Marina Carpano, Antonella Pastini, Estanislao Pavlik et al.
2026-10-01 · DOI: 10.3389/fchbi.2026.1945455Unraveling pH-dependent peptide conformational transitions via integration of main mechanical forces and side-chain interactions
Michele Larocca, Giuseppe Floresta, Daniele Verderese, Agostino Cilibrizzi et al.
2026-09-28 · DOI: 10.3389/fchbi.2026.1914849Bridging AI, molecular dynamics, and experiments for mechanism-aware TCR engineering in cancer immunotherapy
Mario Frezzini, Daniele Narzi
2026-09-08 · DOI: 10.3389/fchbi.2026.1909618Second-generation N,N′-disubstituted aliphatic diamines: discovery of potent hits for multi-species leishmaniasis treatment
Alejandro I. Recio-Balsells, Esteban A. Panozzo-Zenere, Elizabeth M. Coser, Bianca A. Ferreira et al.
2026-09-04 · DOI: 10.3389/fchbi.2026.1888764Structural and functional defects of mitochondrial serine hydroxymethyltransferase genetic variants responsible for a novel neurodevelopmental syndrome
Giovanna Boumis, Sara Breccia, Gianluca Pistoia, Sharon Spizzichino et al.
2026-09-03 · DOI: 10.3389/fchbi.2026.1941005Linking genomes to metabolites in antimicrobial discovery: integrative metagenomic and metabolomic approaches to combat antimicrobial resistance
Swadha Kailoo, Mansavi Bhardwaj, Shafaq Rasool
2026-09-01 · DOI: 10.3389/fchbi.2026.1840907Towards programmable metallonucleases via genetic code expansion
Eryn Lundrigan, Matthew O’Neill, John Paul Pezacki
2026-08-26 · DOI: 10.3389/fchbi.2026.1914162From small molecules to oligonucleotides: artificial intelligence for RNA-targeted drug discovery
Qingwen Chen
2026-08-26 · DOI: 10.3389/fchbi.2026.1915343Molecular hydrogen in cancer: reprogramming oncogenic signaling pathways and emerging pharmacological potential
Anirban Kumar Maity, Ajay Mallick, Debbie C. Crans, Srikanta Goswami et al.
2026-08-24 · DOI: 10.3389/fchbi.2026.1915345Metabolomic profiling for the identification of drug targets in trypanosomes
Maura Rojas-Pirela, Diego Andrade-Alviárez, Wilfredo Quiñones, Ana J. Cáceres et al.
2026-08-24 · DOI: 10.3389/fchbi.2026.1907625Molecular dynamics simulation of the truncated NMDA receptor in a partially restrained active-like state
Xing Liu, Wenjun Zheng
2026-08-17 · DOI: 10.3389/fchbi.2026.1894245Integrating molecular dynamics and machine learning to identify potential apo-state conformational and solvent-exposure signatures associated with resistant KRAS mutants
Katarzyna Mizgalska, Konstancja Urbaniak, Denis J. Imbody, Eric B. Haura et al.
2026-08-05 · DOI: 10.3389/fchbi.2026.1900407Phytochemical interventions in bacterial resistance: plant metabolites as next-generation antibacterial agents
Amin Mahmood Thawabteh, Anwar Ma’ali, Waed Ibdah, Donia Karaman et al.
2026-07-28 · DOI: 10.3389/fchbi.2026.1760834ALS-associated FUS mutations induce site-specific alterations in conformational dynamics and molecular interactions
Christodoulos Amourgianos, Themis P. Exarchos, Panagiotis Vlamos, Marios G. Krokidis et al.
2026-07-23 · DOI: 10.3389/fchbi.2026.1851848Phosphorus fluoride exchange (PFEx): a new frontier in bioconjugation, enzyme inhibition, proximity-induced target-binding and fluorescence probes
Vaibhav Gupta, Nibedita Roy, Vaishnavi Newaskar, Sankar K. Guchhait et al.
2026-07-14 · DOI: 10.3389/fchbi.2026.1879339Unravelling the effects of proline analogues against Trypanosoma cruzi
María Sol Ballari, Flávia S. Damasceno, Marcelo L. Merli, Lucía Fargnoli et al.
2026-07-09 · DOI: 10.3389/fchbi.2026.1848258Engineering Mycobacterium smegmatis to produce oxygenic mycolic acids of Mycobacterium tuberculosis
Udipta Bohara, Liwu Li, Biswarup Mukhopadhyay, Endang Purwantini et al.
2026-06-19 · DOI: 10.3389/fchbi.2026.1809486Zinc-binding proteins in Alzheimer’s disease: mechanisms, therapeutic potential, and natural compound interventions
Riddhi Upadhyay, Susmita Kar, Murugan Sevanan
2026-06-10 · DOI: 10.3389/fchbi.2026.1836070Histaminium decavanadate: a small biomimetic model to study non-covalent interactions between decavanadate and histidine side chains in proteins
L. F. Paredes-Pérez, N. Sánchez-López, D. Ramírez-Contreras, A. Mendoza et al.
2026-06-05 · DOI: 10.3389/fchbi.2026.1824850Editorial: Vanadium biochemistry – highlights from the 13th international vanadium symposium
Isabel Correia, Debbie C. Crans
2026-06-01 · DOI: 10.3389/fchbi.2026.1860732Reviews
Community Reviews
Version History
October 2, 2026 at 9:35 pm
October 2, 2026